Certara, Inc. (CERT) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Certara, Inc.'s filing signal turned positive.

Certara, Inc. is a global leader in biosimulation science, technology, and consulting, leveraging Model-Informed Drug Development (MIDD) to enhance decision-making in the biopharmaceutical and biotech industries. Its solutions aim to increase the probability of success, accelerate development timelines, and reduce costs for new medicines by using biological and statistical models derived from preclinical and clinical data. The company's integrated approach combines biosimulation platforms, scientific informatics, and regulatory science expertise, including AI-driven tools, to support clients from drug discovery through commercialization. Certara's software is used by over 160,000 users globally, including 20 drug regulatory agencies, and its services have supported over 2,600 life sciences companies and academic institutions.

Revenue is generated from software products, including licenses, subscriptions, and maintenance, and from technology-driven and professional services such as implementation and consulting.